论文部分内容阅读
胃癌是世界上最常见的恶性肿瘤之一,其发病率和病死率居各种恶性肿瘤之首,5年生存率仅为5.0%~15.0%~([1])。我们通过比较奥沙利铂联合替吉奥(SOX方案)化疗后对进展期胃癌手术切除率以及临床疗效,证明术前使用奥沙利铂联合替吉奥化疗的重要临床意义。现报道如下。
Gastric cancer is one of the most common malignant tumors in the world. Its morbidity and mortality are the highest among all kinds of malignant tumors. The 5-year survival rate is only 5.0% ~ 15.0% ~ ([1]). We compared the efficacy of oxaliplatin and tegaserod (SOX regimen) chemotherapy in the treatment of advanced gastric cancer and its clinical efficacy, demonstrating the important clinical significance of preoperative use of oxaliplatin in combination with tigoxir chemotherapy. Report as follows now.